Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
In recent years, several associations between common chronic human disorders and altered gut microbiome composition and function have been reported. In most of these reports, treatment regimens were not controlled for and conclusions could thus be confounded by the effects of various drugs on the microbiota, which may obscure microbial causes, protective factors or diagnostically relevant signals. Our study addresses disease and drug signatures in the human gut microbiome of type 2 diabetes mellitus (T2D). Two previous quantitative gut metagenomics studies of T2D patients that were unstratified for treatment yielded divergent conclusions regarding its associated gut microbial dysbiosis. Here we show, using 784 available human gut metagenomes, how antidiabetic medication confounds these results, and analyse in detail the effects of the most widely used antidiabetic drug metformin. We provide support for microbial mediation of the therapeutic effects of metformin through short-chain fatty acid production, as well as for potential microbiota-mediated mechanisms behind known intestinal adverse effects in the form of a relative increase in abundance of Escherichia species. Controlling for metformin treatment, we report a unified signature of gut microbiome shifts in T2D with a depletion of butyrate-producing taxa. These in turn cause functional microbiome shifts, in part alleviated by metformin-induced changes. Overall, the present study emphasizes the need to disentangle gut microbiota signatures of specific human diseases from those of medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“patient treatment with the drug metformin, a variable that subjects had not been stratified for previously, constituted the main determinant of microbial signatures in diabetic cohorts [62].”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [62]
In the citing paper
“This action is an important determinant for the anti-hyperglycemic therapeutic effects, the gastrointestinal side effects and possibly the anti-aging effects of metformin (88, 89).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [88]
In the citing paper
“As for C. elegans, metformin use in humans will change the microbiome.”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [88]
In the citing paper
“Studies comparing individuals with T2D treated or not with metformin identified a higher level of E. coli and a lower level of Intestinibacter in the metformin-treated individuals, while confirming reduced levels of butyrate-producing bacteria such as Roseburia spp., F. prausnitzii, and unnamed Clostridiales in the untreated individuals compared to healthy controls5, 6, 34, 35.”
From The gut microbiome in atherosclerotic cardiovascular disease (2017) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
The SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
UPARSE: highly accurate OTU sequences from microbial amplicon reads
Edgar, R. C. (2013) · Nature Methods · doi:10.1038/nmeth.2604 · Cited by 16,707
FLASH: fast length adjustment of short reads to improve genome assemblies
Magoč, T., & Salzberg, S. L. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr507 · Cited by 15,366
UCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
A new method for non-parametric multivariate analysis of variance
Anderson, M. J. (2001) · Austral Ecology · doi:10.1111/j.1442-9993.2001.01070.pp.x · Cited by 13,828
Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences
Li, W., & Godzik, A. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl158 · Cited by 11,410
VEGAN, a package of R functions for community ecology
Dixon, P. (2003) · Journal of Vegetation Science · doi:10.1111/j.1654-1103.2003.tb02228.x · Cited by 6,824
Cited by
Items 101–200 of 1,006
Gut Microbiome Fermentation Determines the Efficacy of Exercise for Diabetes Prevention
Liu, Y., Wang, Y., Ni, Y., Cheung, C. K. Y., Lam, K. S. L., Wang, Y., Xia, Z., Ye, D., Guo, J., Tse, M. A., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.001 · Cited by 405
Gu, Y., Wang, X., Li, J., Zhang, Y., Zhong, H., Liu, R., Zhang, D., Feng, Q., Xie, X., Hong, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01682-2 · Cited by 401
Self-citationBeyond gut feelings: how the gut microbiota regulates blood pressure
Marques, F. Z., Mackay, C. R., & Kaye, D. M. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.120 · Cited by 397
Mitochondrial control of immunity: beyond ATP
Mehta, M. M., Weinberg, S. E., & Chandel, N. S. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.66 · Cited by 396
Flandroy, L., Poutahidis, T., Berg, G., Clarke, G., Dao, M.-C., Decaestecker, E., Furman, E., Haahtela, T., Massart, S., Plovier, H., et al. (2018) · Science of The Total Environment · doi:10.1016/j.scitotenv.2018.01.288 · Cited by 394
Wang, D. D., Nguyen, L. H., Li, Y., Yan, Y., Ma, W., Rinott, E., Ivey, K. L., Shai, I., Willett, W. C., Hu, F. B., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01223-3 · Cited by 386
The Role of Short Chain Fatty Acids in Inflammation and Body Health
Du, Y., He, C., An, Y., Huang, Y., Zhang, H., Fu, W., Wang, M., Shan, Z., Xie, J., Yang, Y., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137379 · Cited by 384
The Healthy Microbiome—What Is the Definition of a Healthy Gut Microbiome?
Shanahan, F., Ghosh, T. S., & O’Toole, P. W. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.057 · Cited by 383
Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis
Wen, C., Zheng, Z., Shao, T., Liu, L., Xie, Z., Le Chatelier, E., He, Z., Zhong, W., Fan, Y., Zhang, L., et al. (2017) · Genome Biology · doi:10.1186/s13059-017-1271-6 · Cited by 382
Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)
Zhang, Y., Gu, Y., Ren, H., Wang, S., Zhong, H., Zhao, X., Ma, J., Gu, X., Xue, Y., Huang, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18414-8 · Cited by 380
Self-citationFacchin, S., Bertin, L., Bonazzi, E., Lorenzon, G., De Barba, C., Barberio, B., Zingone, F., Maniero, D., Scarpa, M., Ruffolo, C., et al. (2024) · Life · doi:10.3390/life14050559 · Cited by 380
Precup, G., & Vodnar, D.-C. (2019) · British Journal of Nutrition · doi:10.1017/s0007114519000680 · Cited by 378
“However, other studies did not find correlations between obesity(13,66,67), type 1 or type 2 diabetes(68,69) and lower levels of Prevotella.”
Tong, X., Xu, J., Lian, F., Yu, X., Zhao, Y., Xu, L., Zhang, M., Zhao, X., Shen, J., Wu, S., et al. (2018) · mBio · doi:10.1128/mbio.02392-17 · Cited by 378
Self-citationModulating the microbiome to improve therapeutic response in cancer
McQuade, J. L., Daniel, C. R., Helmink, B. A., & Wargo, J. A. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30952-5 · Cited by 376
Metabolic Effects of Dietary Nitrate in Health and Disease
Lundberg, J. O., Carlström, M., & Weitzberg, E. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.007 · Cited by 374
The Microbiome and Human Biology
Knight, R., Callewaert, C., Marotz, C., Hyde, E. R., Debelius, J. W., McDonald, D., & Sogin, M. L. (2017) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083115-022438 · Cited by 373
Intestinal Lactobacillus in health and disease, a driver or just along for the ride?
Heeney, D. D., Gareau, M. G., & Marco, M. L. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.08.004 · Cited by 369
Colorectal Cancer and the Human Gut Microbiome: Reproducibility with Whole-Genome Shotgun Sequencing
Vogtmann, E., Hua, X., Zeller, G., Sunagawa, S., Voigt, A. Y., Hercog, R., Goedert, J. J., Shi, J., Bork, P., & Sinha, R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0155362 · Cited by 366
“And given previous work that suggests that microbial associations with Type 2 diabetes may differ by population [22, 23], although these differences may be driven by metformin use [24], it is encouraging that some of the associations were robust between populations in the United States and France from different years.”
Self-citationGlycine Metabolism and Its Alterations in Obesity and Metabolic Diseases
Alves, A., Bassot, A., Bulteau, A.-L., Pirola, L., & Morio, B. (2019) · Nutrients · doi:10.3390/nu11061356 · Cited by 365
Butyrate in Energy Metabolism: There Is Still More to Learn
Zhang, L., Liu, C., Jiang, Q., & Yin, Y. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.12.003 · Cited by 364
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
“It is interesting to note that the abundance of butyrateproducing bacteria decreased in both prediabetic and T2DM patients.(249,250) Insulin resistance has been found to be strongly related to microbial dysfunction.”
Review of the relationships among polysaccharides, gut microbiota, and human health
Song, Q., Wang, Y., Huang, L., Shen, M., Yu, Y., Yu, Q., Chen, Y., & Xie, J. (2021) · Food Research International · doi:10.1016/j.foodres.2020.109858 · Cited by 357
Brunkwall, L., & Orho-Melander, M. (2017) · Diabetologia · doi:10.1007/s00125-017-4278-3 · Cited by 355
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Sphingolipids produced by gut bacteria enter host metabolic pathways impacting ceramide levels
Johnson, E. L., Heaver, S. L., Waters, J. L., Kim, B. I., Bretin, A., Goodman, A. L., Gewirtz, A. T., Worgall, T. S., & Ley, R. E. (2020) · Nature Communications · doi:10.1038/s41467-020-16274-w · Cited by 352
Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential
Saus, E., Iraola-Guzmán, S., Willis, J. R., Brunet-Vega, A., & Gabaldón, T. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.05.001 · Cited by 350
Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases
Belizário, J. E., Faintuch, J., & Garay-Malpartida, M. (2018) · Mediators of Inflammation · doi:10.1155/2018/2037838 · Cited by 341
Exercise Training Modulates Gut Microbiota Profile and Improves Endotoxemia
MOTIANI, K. K., COLLADO, M. C., ESKELINEN, J.-J., VIRTANEN, K. A., LÖYTTYNIEMI, E., SALMINEN, S., NUUTILA, P., KALLIOKOSKI, K. K., & HANNUKAINEN, J. C. (2020) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002112 · Cited by 333
Sáez-Lara, M., Robles-Sanchez, C., Ruiz-Ojeda, F., Plaza-Diaz, J., & Gil, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060928 · Cited by 328
Bioaccumulation of therapeutic drugs by human gut bacteria
Klünemann, M., Andrejev, S., Blasche, S., Mateus, A., Phapale, P., Devendran, S., Vappiani, J., Simon, B., Scott, T. A., Kafkia, E., et al. (2021) · Nature · doi:10.1038/s41586-021-03891-8 · Cited by 327
Self-citationGut microbiome, big data and machine learning to promote precision medicine for cancer
Cammarota, G., Ianiro, G., Ahern, A., Carbone, C., Temko, A., Claesson, M. J., Gasbarrini, A., & Tortora, G. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0327-3 · Cited by 324
Gut reactions: Breaking down xenobiotic–microbiome interactions
Clarke, G., Sandhu, K. V., Griffin, B. T., Dinan, T. G., Cryan, J. F., & Hyland, N. P. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.015768 · Cited by 319
Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians
Allaband, C., McDonald, D., Vázquez-Baeza, Y., Minich, J. J., Tripathi, A., Brenner, D. A., Loomba, R., Smarr, L., Sandborn, W. J., Schnabl, B., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.09.017 · Cited by 318
Vallianou, N., Stratigou, T., Christodoulatos, G. S., & Dalamaga, M. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00352-2 · Cited by 316
Palleja, A., Kashani, A., Allin, K. H., Nielsen, T., Zhang, C., Li, Y., Brach, T., Liang, S., Feng, Q., Jørgensen, N. B., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0312-1 · Cited by 315
Self-citationHost Genetics and Gut Microbiome: Challenges and Perspectives
Kurilshikov, A., Wijmenga, C., Fu, J., & Zhernakova, A. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.06.003 · Cited by 309
Hypothalamic AMPK: a canonical regulator of whole-body energy balance
López, M., Nogueiras, R., Tena-Sempere, M., & Diéguez, C. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.67 · Cited by 309
MICOM: Metagenome-Scale Modeling To Infer Metabolic Interactions in the Gut Microbiota
Diener, C., Gibbons, S. M., & Resendis-Antonio, O. (2020) · mSystems · doi:10.1128/msystems.00606-19 · Cited by 309
Advancing human gut microbiota research by considering gut transit time
Procházková, N., Falony, G., Dragsted, L. O., Licht, T. R., Raes, J., & Roager, H. M. (2023) · Gut · doi:10.1136/gutjnl-2022-328166 · Cited by 308
Self-citationDay, E. A., Ford, R. J., Smith, B. K., Mohammadi-Shemirani, P., Morrow, M. R., Gutgesell, R. M., Lu, R., Raphenya, A. R., Kabiri, M., McArthur, A. G., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0146-4 · Cited by 307
Chen, Z., Radjabzadeh, D., Chen, L., Kurilshikov, A., Kavousi, M., Ahmadizar, F., Ikram, M. A., Uitterlinden, A. G., Zhernakova, A., Fu, J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.18811 · Cited by 305
The food-gut axis: lactic acid bacteria and their link to food, the gut microbiome and human health
De Filippis, F., Pasolli, E., & Ercolini, D. (2020) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa015 · Cited by 303
The Microbiome and Risk for Obesity and Diabetes
Komaroff, A. L. (2017) · JAMA · doi:10.1001/jama.2016.20099 · Cited by 293
Interindividual variability in gut microbiota and host response to dietary interventions
Healey, G. R., Murphy, R., Brough, L., Butts, C. A., & Coad, J. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nux062 · Cited by 292
Toward Accurate and Quantitative Comparative Metagenomics
Nayfach, S., & Pollard, K. S. (2016) · Cell · doi:10.1016/j.cell.2016.08.007 · Cited by 292
A faecal microbiota signature with high specificity for pancreatic cancer
Kartal, E., Schmidt, T. S. B., Molina-Montes, E., Rodríguez-Perales, S., Wirbel, J., Maistrenko, O. M., Akanni, W. A., Alashkar Alhamwe, B., Alves, R. J., Carrato, A., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-324755 · Cited by 290
Self-citationMurphy, R., Tsai, P., Jüllig, M., Liu, A., Plank, L., & Booth, M. (2017) · Obesity Surgery · doi:10.1007/s11695-016-2399-2 · Cited by 285
Mayhew, D., Devos, N., Lambert, C., Brown, J. R., Clarke, S. C., Kim, V. L., Magid-Slav, M., Miller, B. E., Ostridge, K. K., Patel, R., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-210408 · Cited by 285
Gut Microbiota Composition and Blood Pressure: The CARDIA Study
Sun, S., Lulla, A., Sioda, M., Winglee, K., Wu, M. C., Jacobs, D. R., Shikany, J. M., Lloyd-Jones, D. M., Launer, L. J., Fodor, A. A., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12109 · Cited by 282
Microbiome and metabolome features of the cardiometabolic disease spectrum
Fromentin, S., Forslund, S. K., Chechi, K., Aron-Wisnewsky, J., Chakaroun, R., Nielsen, T., Tremaroli, V., Ji, B., Prifti, E., Myridakis, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01688-4 · Cited by 281
Self-citationAkkermansia muciniphila mediates negative effects of IFNγ on glucose metabolism
Greer, R. L., Dong, X., Moraes, A. C. F., Zielke, R. A., Fernandes, G. R., Peremyslova, E., Vasquez-Perez, S., Schoenborn, A. A., Gomes, E. P., Pereira, A. C., et al. (2016) · Nature Communications · doi:10.1038/ncomms13329 · Cited by 279
Arrhythmic Gut Microbiome Signatures Predict Risk of Type 2 Diabetes
Reitmeier, S., Kiessling, S., Clavel, T., List, M., Almeida, E. L., Ghosh, T. S., Neuhaus, K., Grallert, H., Linseisen, J., Skurk, T., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.004 · Cited by 279
Mohammed, I., Hollenberg, M. D., Ding, H., & Triggle, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718942 · Cited by 278
Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans
Meijnikman, A. S., Gerdes, V. E., Nieuwdorp, M., & Herrema, H. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00192 · Cited by 278
Evolutionary and Ecological Consequences of Gut Microbial Communities
Moran, N. A., Ochman, H., & Hammer, T. J. (2019) · Annual Review of Ecology, Evolution, and Systematics · doi:10.1146/annurev-ecolsys-110617-062453 · Cited by 275
Host-microbe-drug-nutrient screen identifies bacterial effectors of metformin therapy
Pryor, R., Norvaisas, P., Marinos, G., Best, L., Thingholm, L. B., Quintaneiro, L. M., De Haes, W., Esser, D., Waschina, S., Lujan, C., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.003 · Cited by 274
Molinaro, A., Bel Lassen, P., Henricsson, M., Wu, H., Adriouch, S., Belda, E., Chakaroun, R., Nielsen, T., Bergh, P.-O., Rouault, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19589-w · Cited by 271
Self-citationGut microbiota influence in type 2 diabetes mellitus (T2DM)
Cunningham, A. L., Stephens, J. W., & Harris, D. A. (2021) · Gut Pathogens · doi:10.1186/s13099-021-00446-0 · Cited by 270
Wirbel, J., Zych, K., Essex, M., Karcher, N., Kartal, E., Salazar, G., Bork, P., Sunagawa, S., & Zeller, G. (2021) · Genome Biology · doi:10.1186/s13059-021-02306-1 · Cited by 269
Self-citationRevisit gut microbiota and its impact on human health and disease
Ding, R.-X., Goh, W.-R., Wu, R.-N., Yue, X.-Q., Luo, X., Khine, W. W. T., Wu, J.-R., & Lee, Y.-K. (2019) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2018.12.012 · Cited by 268
Precision nutrition for prevention and management of type 2 diabetes
Wang, D. D., & Hu, F. B. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30037-8 · Cited by 267
Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function
Cussotto, S., Strain, C. R., Fouhy, F., Strain, R. G., Peterson, V. L., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5006-5 · Cited by 266
Bauer, P. V., Duca, F. A., Waise, T. M. Z., Rasmussen, B. A., Abraham, M. A., Dranse, H. J., Puri, A., O’Brien, C. A., & Lam, T. K. T. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.019 · Cited by 265
Exposing the exposures responsible for type 2 diabetes and obesity
Franks, P. W., & McCarthy, M. I. (2016) · Science · doi:10.1126/science.aaf5094 · Cited by 265
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders
Metwaly, A., Reitmeier, S., & Haller, D. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00581-2 · Cited by 264
Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications
Le Bastard, Q., Al‐Ghalith, G. A., Grégoire, M., Chapelet, G., Javaudin, F., Dailly, E., Batard, E., Knights, D., & Montassier, E. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14451 · Cited by 263
Mobini, R., Tremaroli, V., Ståhlman, M., Karlsson, F., Levin, M., Ljungberg, M., Sohlin, M., Bertéus Forslund, H., Perkins, R., Bäckhed, F., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12861 · Cited by 263
Metformin as Anti-Aging Therapy: Is It for Everyone?
Soukas, A. A., Hao, H., & Wu, L. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.07.015 · Cited by 263
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
The gut microbiota: A treasure for human health
Li, D., Wang, P., Wang, P., Hu, X., & Chen, F. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.08.003 · Cited by 261
Ma, Z., Zuo, T., Frey, N., & Rangrez, A. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01946-6 · Cited by 259
Yuille, S., Reichardt, N., Panda, S., Dunbar, H., & Mulder, I. E. (2018) · PLOS ONE · doi:10.1371/journal.pone.0201073 · Cited by 257
Understanding and overcoming metformin gastrointestinal intolerance
Bonnet, F., & Scheen, A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12854 · Cited by 256
Machine learning for microbiologists
Asnicar, F., Thomas, A. M., Passerini, A., Waldron, L., & Segata, N. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00984-1 · Cited by 256
Sung, J., Kim, S., Cabatbat, J. J. T., Jang, S., Jin, Y.-S., Jung, G. Y., Chia, N., & Kim, P.-J. (2017) · Nature Communications · doi:10.1038/ncomms15393 · Cited by 254
Microbiome as a therapeutic target in alcohol-related liver disease
Sarin, S. K., Pande, A., & Schnabl, B. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.019 · Cited by 253
Taking it Personally: Personalized Utilization of the Human Microbiome in Health and Disease
Zmora, N., Zeevi, D., Korem, T., Segal, E., & Elinav, E. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2015.12.016 · Cited by 252
“Recently, a follow-up study suggested that this association was at least partially driven by metformin usage by some diabetic individuals in these cohorts (Forslund et al., 2015).”
Gut microbiota in the pathogenesis and therapeutic approaches of diabetes
Crudele, L., Gadaleta, R. M., Cariello, M., & Moschetta, A. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104821 · Cited by 251
“For example, excess in metformin-induced Escherichia enrichment may result in abdominal discomfort, 56 resembling symptoms associated to irritable bowel syndrome.”
Problems with the concept of gut microbiota dysbiosis
Brüssow, H. (2020) · Microbial Biotechnology · doi:10.1111/1751-7915.13479 · Cited by 250
Richards, J. L., Yap, Y. A., McLeod, K. H., Mackay, C. R., & Mariño, E. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.29 · Cited by 250
Inflammageing and metaflammation: The yin and yang of type 2 diabetes
Prattichizzo, F., De Nigris, V., Spiga, R., Mancuso, E., La Sala, L., Antonicelli, R., Testa, R., Procopio, A. D., Olivieri, F., & Ceriello, A. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2017.10.003 · Cited by 249
Kapil, V., Khambata, R. S., Jones, D. A., Rathod, K., Primus, C., Massimo, G., Fukuto, J. M., & Ahluwalia, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019240 · Cited by 248
Linking the Microbiota, Chronic Disease, and the Immune System
Hand, T. W., Vujkovic-Cvijin, I., Ridaura, V. K., & Belkaid, Y. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.08.003 · Cited by 247
Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic
Mendrick, D. L., Diehl, A. M., Topor, L. S., Dietert, R. R., Will, Y., La Merrill, M. A., Bouret, S., Varma, V., Hastings, K. L., Schug, T. T., et al. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfx233 · Cited by 246
Human trials exploring anti-aging medicines
Guarente, L., Sinclair, D. A., & Kroemer, G. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.007 · Cited by 244
Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review
Bjornstad, P., & Eckel, R. H. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1101-6 · Cited by 243
Microbiota Metabolites in Health and Disease
McCarville, J. L., Chen, G. Y., Cuevas, V. D., Troha, K., & Ayres, J. S. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-071219-125715 · Cited by 241
Ke, C., Narayan, K. M. V., Chan, J. C. N., Jha, P., & Shah, B. R. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00669-4 · Cited by 239
Kishikawa, T., Maeda, Y., Nii, T., Motooka, D., Matsumoto, Y., Matsushita, M., Matsuoka, H., Yoshimura, M., Kawada, S., Teshigawara, S., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215743 · Cited by 238
Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers
Liu, X., Romero, I. L., Litchfield, L. M., Lengyel, E., & Locasale, J. W. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.005 · Cited by 236
Metformin and Systemic Metabolism
He, L. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.09.001 · Cited by 235
“But metformin can alter the composition of intestinal microbiota in HFD-fed and diabetic mice and reverse insulin resistance [87, 88].”
Zhao, L., Lou, H., Peng, Y., Chen, S., Zhang, Y., & Li, X. (2019) · Endocrine · doi:10.1007/s12020-019-02103-8 · Cited by 235
Yao, Y., Yan, L., Chen, H., Wu, N., Wang, W., & Wang, D. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153268 · Cited by 235
Adjusting for age improves identification of gut microbiome alterations in multiple diseases
Ghosh, T. S., Das, M., Jeffery, I. B., & O'Toole, P. W. (2020) · eLife · doi:10.7554/elife.50240 · Cited by 233
“Another recent study investigating the effect of metformin on the gut microbiome of two of the T2D cohorts analysed in the current study identified Lactobacillus salivarius to be affected by metformin, accompanied by an increase in Escherichia (Forslund et al., 2015).”
InfluentialCarlström, M., & Larsson, S. C. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy014 · Cited by 233
The critical role of Faecalibacterium prausnitzii in human health: An overview
Leylabadlo, H. E., Ghotaslou, R., Feizabadi, M. M., Farajnia, S., Moaddab, S. Y., Ganbarov, K., Khodadadi, E., Tanomand, A., Sheykhsaran, E., Yousefi, B., et al. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104344 · Cited by 229
Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota
Lindell, A. E., Zimmermann-Kogadeeva, M., & Patil, K. R. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00681-5 · Cited by 228
Metformin ameliorates core deficits in a mouse model of fragile X syndrome
Gantois, I., Khoutorsky, A., Popic, J., Aguilar-Valles, A., Freemantle, E., Cao, R., Sharma, V., Pooters, T., Nagpal, A., Skalecka, A., et al. (2017) · Nature Medicine · doi:10.1038/nm.4335 · Cited by 228
Type 2 diabetes influences bacterial tissue compartmentalisation in human obesity
Anhê, F. F., Jensen, B. A. H., Varin, T. V., Servant, F., Van Blerk, S., Richard, D., Marceau, S., Surette, M., Biertho, L., Lelouvier, B., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0178-9 · Cited by 227
Combinatorial, additive and dose-dependent drug–microbiome associations
Forslund, S. K., Chakaroun, R., Zimmermann-Kogadeeva, M., Markó, L., Aron-Wisnewsky, J., Nielsen, T., Moitinho-Silva, L., Schmidt, T. S. B., Falony, G., Vieira-Silva, S., et al. (2021) · Nature · doi:10.1038/s41586-021-04177-9 · Cited by 226
Self-citation
Metadata
- Authors
- MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., Krogh Pedersen, H., Arumugam, M., Kristiansen, K., Yvonne Voigt, A., Vestergaard, H., Hercog, R., Igor Costea, P., Roat Kultima, J., Li, J., Jørgensen, T., Levenez, F., Dore, J., Bjørn Nielsen, H., Brunak, S., Raes, J., Hansen, T., Wang, J., Dusko Ehrlich, S., Bork, P., & Pedersen, O.
- Affiliations
- Vrije Universiteit Brussel (BE)
- University of Copenhagen (DK)
- Rega Institute for Medical Research (BE)
- European Molecular Biology Laboratory (DE)
- Microbiologie de l’alimentation au service de la santé (FR)
- BGI Group (China) (CN)
- Corresponding author
- Pedersen, Oluf
- ORCID
- Venue
- Nature
- Published
- 2015-12-02
- Volume
- 528
- Issue
- 7581
- Pages
- 262-266
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4681099
- OpenAlex
- W2188930066
- Cited by
- 2,116
- References
- 49
- Citations by year
- 2026: 113 · 2025: 167 · 2024: 212 · 2023: 194 · 2022: 253 · 2021: 270 · 2020: 256 · 2019: 185 · 2018: 197 · 2017: 150 · 2016: 112 · 2015: 3
- FWCI
- 66.83
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-05-04)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Socio-Environmental Systems Modeling (acceptedVersion)
- HAL (submittedVersion, cc-by-nc-nd)
- HAL (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Innovationsfonden
- European Molecular Biology Laboratory
- European Commission (600375, 2007–2013, FP7 2007-2013, HORIZON2020, FP7/2007, 305312, 201052, 261376)
- Agence Nationale de la Recherche (ANR-11-DPBS-0001)
- Lundbeckfonden
- Novo Nordisk
- Göteborgs Universitet
- Copenhagen Graduate School for Nanoscience and Nanotechnology
- Novo Nordisk Foundation Center for Basic Metabolic Research
- H. Lundbeck A/S
- FP7 Ideas: European Research Council (268985)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- type 2 diabetes, gut microbiota, metformin, antidiabetic drugs, dysbiosis, confounding by treatment, short-chain fatty acids, butyrate, Escherichia, metagenome-wide association study
- MeSH terms
- Gastrointestinal Microbiome, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Metformin, RNA, Ribosomal, 16S, Biodiversity, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.